Fox Run Management L.L.C. Invests $448,000 in Omnicell, Inc. $OMCL

Key Points

• Fox Run Management L.L.C. invested approximately $448,000 in Omnicell, Inc., acquiring 12,815 shares of the company's stock in the first quarter.
• Analysts have varying outlooks on Omnicell's stock, with a current average target price of $46.71 and three hold ratings alongside five buy ratings.
• Omnicell reported a year-over-year revenue increase of 5.0% for the last quarter, with earnings per share of $0.45, exceeding expectations.

Fox Run Management L.L.C. acquired a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,815 shares of the company's stock, valued at approximately $448,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Summit Investment Advisors Inc. increased its position in Omnicell by 6.9% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock worth $213,000 after purchasing an additional 307 shares in the last quarter. Diversified Trust Co raised its stake in Omnicell by 2.3% in the 1st quarter. Diversified Trust Co now owns 22,660 shares of the company's stock valued at $792,000 after purchasing an additional 513 shares during the last quarter. Bridge City Capital LLC raised its stake in Omnicell by 1.6% in the 1st quarter. Bridge City Capital LLC now owns 40,136 shares of the company's stock valued at $1,403,000 after purchasing an additional 650 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Omnicell by 4.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,832 shares of the company's stock valued at $553,000 after purchasing an additional 696 shares during the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in Omnicell in the 4th quarter valued at about $37,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Trading Up 5.4%

Shares of NASDAQ OMCL traded up $1.73 on Friday, reaching $33.62. 863,923 shares of the company traded hands, compared to its average volume of 571,833. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.74. The company has a 50 day moving average of $29.53 and a 200 day moving average of $31.99. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.54 billion, a PE ratio of 67.24, a P/E/G ratio of 9.27 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The business had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same quarter in the previous year, the business earned $0.51 EPS. The company's revenue for the quarter was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on OMCL shares. Piper Sandler cut their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Wells Fargo & Company boosted their target price on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Bank of America boosted their target price on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Wall Street Zen downgraded shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Benchmark cut their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $46.71.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.